EU Investment Programme
Participation in international exhibitions - a meaningful investment that promotes enterprise progress, technology deployment and export market development.
Increasing export volumes every year is crucial for the growth of Lithuanian biotechnology companies; therefore participation in international exhibitions is especially vital to achieving the goals of increasing the profitability of the company, technological progress and seeking new opportunities for business development.
Participating in various targeted international exhibitions, UAB SatiMed is convinced that it is a meaningful investment that presents the company's activities, unique biotechnological abilities, meeting existing clients and partners, and getting acquainted with the latest innovations in medical, cosmetic and functional food technologies. This is an excellent opportunity for the company to take a close look at the progress of its competitors, search for new customers, and attend specialized workshops during the exhibition.
To this end, UAB SatiMed announced in 2019. We have started the implementation of the project "Development and Strengthening of Export Markets of UAB "SatiMed" under Measure Nr. 03.2.1-LVPA-K-801 New Opportunities EN. The total eligible cost of the project is EUR 87 476.00. The European Regional Development Fund funds the project.
The project is designed to maintain, strengthen and expand the company's existing export position by participating in international exhibitions 2019-2020, which will present products made to the applicant's technological patents and licenses for a healthy lifestyle. UAB SatiMed exports most of its production to the US, so it is crucial to strengthen our position in the most significant global market further, as well as to seek new markets in the European Union.
Project: Development and strengthening of export markets of UAB SatiMed
Plan No .: 03.2.1-LVPA-K-801-05-0012
Project activities:Presentation of the company and its products at international exhibitions in Germany, the United Kingdom, and the United States.